and 12 females for whom intracorporeal orthotopic neobladder (ONB) (n¼15) and ileal conduit (IC) (n¼35) were performed. ORC included 31 males and 21 females for whom ONB and IC were performed in 41 and 11 patients, respectively. There was a significant difference in global health status (QL2) for iRARC in comparison to ORC (median (range)) [75(0-100) vs 33.3(0-100), p¼ 0.003] and a difference across functional scales for iRARC in comparison to ORC group (p<0.05). Also, iRARC showed statistically significant lower symptom scales in comparison to ORC groups (p<0.05). (Figure 1) CONCLUSIONS: iRARC seems to provide patients with a better HRQOL compared to ORC. Large prospective studies including matched groups are still needed to assess HRQOL in these patients. However, our results suggest that HRQOL is an important outcome measure when assessing the potential benefits of iRARC and ORC.
INTRODUCTION AND OBJECTIVES: Presence of muscle in transurethral resection of bladder tumor (TURBT) specimens is an important indication of quality of endoscopic resection. The presence or absence of muscle should be noted by the pathologist, and a sample is usually only considered adequate if there is muscle present. The objective of this study is to create natural language processing to evaluate the quality of TURBT specimens amongst many surgeons at a large institution.
METHODS: The Enterprise Data Warehouse at Northwestern University was used to perform a retrospective analysis of patients undergoing TURBT over 10 years. Natural language processing was used to extract stage, grade, and muscle presence information from TURBT pathology reports. Initial construction of programming language was performed using a manually-created training set of 867 TURBTs. Outcomes included (1) rates of pathology reports mentioning the presence or absence of muscle, and (2) for pathology reports that mentioned muscle, rates of muscle presence in the surgical specimen. Since tumors that were cT2 involved muscle, these were excluded from the analysis. Logistic regression analysis was performed to determine associations with muscle being mentioned and present.
RESULTS: 3042 TURBTs from 1324 patients performed by 20 surgeons were included in the database. Validation of 150 randomlyselected data points generated with our algorithm revealed accuracy of 98.7%. Muscle was mentioned in 72% of all 2918 TURBTs stage <T2. Muscle was more likely to be mentioned in patients with T1 disease than Ta, CIS, or no cancer (Table 1 ). In the 2099 reports that mentioned muscle, only 50% of patients with T1 had muscle in the specimen, but patients with T1 disease were more likely to have muscle than Ta disease (Table 1) . Mention of muscle in the pathology report was associated with T1 disease (OR 6.9, p<0 .01) and oncology-fellowship-trained surgeon (OR 2.2, 95% CI 1.7-2.9, p<0.01).
CONCLUSIONS: Automated natural-language processing algorithm was used to create a TURBT database for quality improvement. Patients with T1 disease are more likely to have muscle mentioned and present in the report, and variations in muscle sampling exist amongst surgeons. This algorithm could be portable among medical systems and allow for large-scale quality initiatives between institutions.
Source of Funding: Use of the Northwestern Medicine Enterprise Data Warehouse was in part supported by Northwestern University Clinical and Translational Sciences Institute (NUCATS) grant UL1RR025741.
MP10-19 SYSTEMIC THERAPY AND OVERALL SURVIVAL TRENDS IN PATIENTS WITH NON-UROTHELIAL HISTOLOGIC VARIANTS OF MUSCLE INVASIVE BLADDER CANCER UNDERGOING RADICAL CYSTECTOMY
Shreyas Joshi*, Elizabeth Handorf, Andres Correa, Benjamin ristau, Michael Haifler, Robert Uzzo, Richard Greenberg, David Chen, Rosalia Viterbo, Alexander Kutikov, Daniel Geynisman, Marc Smaldone, Philadelphia, PA INTRODUCTION AND OBJECTIVES: Histological variants of Urothelial carcinoma (UC) of the bladder have a poorer prognosis than histologically pure TCC, and the role of neoadjuvant chemotherapy (NAC) is unclear. Our objective was to evaluate NAC practice patterns and survival outcomes in patients with histologic variants undergoing radical cystectomy (RC) using a large national tumor registry.
METHODS: Patients with cT2-4N0-3Mx muscle invasive bladder cancer (MIBC) who underwent RC from 2003-2014 were selected from the National Cancer Database (NCDB). Patients were categorized by histology code as pure UC or histologic variants. Adjusting for patient and clinical characteristics, generalized estimating equations were used to test the association between histology and receipt of NAC. The association between receipt of NAC and overall survival (OS) was evaluated using Kaplan Meier curves and Cox regression models.
RESULTS: In 23,723 patients meeting inclusion criteria, receipt of NAC in histologic variants was less (12-15%) than in pure UC (28%), with the exception of micropapillary disease (29%) [ Table 1 ]. Median OS was lower in variant histologies than for pure UC (11.1 -29.2 vs. 39.0 months). Receipt of NAC was associated with improved survival compared to RC or RC+adjuvant chemotherapy in patients with pure UC (HR 0.88, p < 0.0001). There was no evidence of a survival benefit for NAC in the variant histologies, or that treatment effects differed by histology (P-val for interaction¼0.87).
CONCLUSIONS: In the NCDB, a substantial proportion of patients (15%) with histologic variants of MIBC undergoing RC receive NAC in the absence of a proven survival benefit. Clinical trials inclusive of patients with variant histologies are necessary to elucidate the role of NAC prior to RC. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e115
